Clinical trials: Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT).
- Trial name
- PROTECT (NCT07647029)
- Testing
- Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Fudan University